Skip to main content
SpringerLink
Log in

Critical Issues in Experimental Models

  • Reference work entry
Drug Discovery and Evaluation: Pharmacological Assays

  • 184 Accesses

Abstract

Cardiovascular, cerebrovascular, and venous thromboembolic disorders continue to be the leading causes of death throughout the world. Over the past two decades, great advances have been made in the pharmacological treatment and prevention of arterial and venous thrombotic disorders (e.g., tissue plasminogen activators, platelet GPIIb/IIIa antagonists, and ADP receptor antagonists such as clopidogrel/prasugrel/ticagrelor, low molecular weight heparins, direct anti-Xa, and direct thrombin inhibitors). New research is leading to the next generation of antithrombotic compounds such as direct coagulation FVIIa inhibitors, tissue factor pathway inhibitors, gene therapy, and orally active direct thrombin inhibitors and coagulation factor Xa (FXa) inhibitors. In vitro assays as well as animal models of thrombosis have played and will continue to play crucial roles in the discovery and validation of novel drug targets, the selection of new agents for clinical evaluation, and the provision of dosing and safety information for clinical trials. In addition, these models have provided valuable information regarding the mechanisms of these new agents and the interactions between antithrombotic agents that work by different mechanisms. This comprehensive chapter presents the pivotal models that led to the development of drugs that have proven to be effective clinically.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 2,999.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 5,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References and Further Reading

  • Agnelli G, Pascucci C, Cosmi B, Nenci GG (1990) The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 63:204–207

    CAS  PubMed  Google Scholar 

  • Cohen M, Demers C, Gurfinkel EP et al (1998) Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 82:19L–24L

    Article  CAS  PubMed  Google Scholar 

  • Collen D, Topol EJ, Tiefenbrunn AJ et al (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70:1012–1017

    Article  CAS  PubMed  Google Scholar 

  • Coller BS, Folts JD, Scudder LE, Smith SR (1986) Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68:783–786

    CAS  PubMed  Google Scholar 

  • Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R (1989) Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 80(6):1766–1774

    Article  CAS  PubMed  Google Scholar 

  • EPIC Investigators (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881–886

    Article  Google Scholar 

  • Fitzgerald DJ, Wright F, FitzGerald GA (1989) Increased thromboxane biosynthesis during coronary thrombolysis: evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 65:83–94

    Article  CAS  PubMed  Google Scholar 

  • Leadley RJJ, Kasiewski CJ, Bostwick JS et al (1998) Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol 18:908–914

    Article  CAS  PubMed  Google Scholar 

  • Lynch JJJ, Sitko GR, Lehman ED, Vlasuk GP (1995) Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemost 74:640–645

    CAS  PubMed  Google Scholar 

  • Matsuo O, Rijken DC, Collen D (1981) Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 291:590–591

    Article  CAS  PubMed  Google Scholar 

  • Nicolini FA, Lee P, Rios G et al (1994) Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 89:1802–1809

    Article  CAS  PubMed  Google Scholar 

Use of Positive Control

  • Schumacher WA, Heran CL, Steinbacher TE (1996) Low-molecular-weight heparin (Fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol 28:19–25

    Article  CAS  PubMed  Google Scholar 

Evaluation of Bleeding Tendency

  • Antman EM, TIMI 9B Investigators (1996) Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 4:911–921

    Article  Google Scholar 

  • Bernardi MM, Califf RM, Kleiman N et al (1993) Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Am J Cardiol 72:1121–1125

    Article  CAS  PubMed  Google Scholar 

  • Bick RL (1995) Laboratory evaluation of platelet dysfunction. Clin Lab Med 15:1–38

    CAS  PubMed  Google Scholar 

  • Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb/IIIa Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782

    Article  Google Scholar 

  • Rodgers RPC, Levin J (1990) A critical reappraisal of the bleeding time. Semin Thromb Hemost 16:1–20

    Article  CAS  PubMed  Google Scholar 

  • Sloan MA, Gore JM (1992) Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am J Cardiol 69:21A–38A

    Article  CAS  PubMed  Google Scholar 

  • Stieg PE, Kase CS (1998) Intracranial hemorrhage: diagnosis and emergency management. Neurol Clin 16:373–390

    Article  CAS  PubMed  Google Scholar 

Selection of Models Based on Species-Dependent Pharmacology/Physiology

  • Bostwick JS, Kasiewski CJ, Chu V et al (1996) Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thromb Res 82:495–507

    Article  CAS  PubMed  Google Scholar 

  • Cook NS, Zerwes H-G, Tapparelli C et al (1993) Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemost 70:531–539

    CAS  PubMed  Google Scholar 

  • Cook JJ, Holahan MA, Lyle EA et al (1996) Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 278:62–73

    CAS  PubMed  Google Scholar 

  • Cox D, Motoyama Y, Seki J et al (1992) Pentamidine: a non-peptide GPIIb/IIIa antagonist – in vitro studies on platelets from humans and other species. Thromb Haemost 68:731–736

    CAS  PubMed  Google Scholar 

  • Nutt EM, Jain D, Lenny AB et al (1991) Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 285:37–44

    Article  CAS  PubMed  Google Scholar 

  • Panzer-Knodle S, Taite BB, Mehrotra DV et al (1993) Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J Pharmacol Toxicol Methods 30:47–53

    Article  CAS  PubMed  Google Scholar 

  • Taniuchi Y, Sakai Y, Hisamichi N et al (1998) Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 79:543–548

    CAS  PubMed  Google Scholar 

  • Tidwell RR, Webster WP, Shaver SR, Geratz JD (1980) Strategies for anticoagulation with synthetic protease inhibitors: Xa inhibitors versus thrombin inhibitors. Thromb Res 19:339–349

    Article  CAS  PubMed  Google Scholar 

Selection of Models Based on Pharmacokinetics

  • Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351–380

    Article  CAS  PubMed  Google Scholar 

  • Sanderson PEJ, Cutrona KJ, Dorsey BD et al (1998) L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett 8:817–822

    Article  CAS  PubMed  Google Scholar 

Clinical Relevance of Data Derived from Experimental Models

  • Bugge TH, Suh TT, Flick MJ et al (1995) The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270:16886–16894

    Article  CAS  PubMed  Google Scholar 

  • Bugge TH, Xiao Q, Kombrinck KW et al (1996) Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 93:6258–6263

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Carmeliet P, Stassen JM, Schoonjans L et al (1993) Plasminogen activator inhibitor-1 gene-deficient mice. J Clin Invest 92:2756–2760

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Carmeliet P, Schoonjans L, Kieckens L et al (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419–424

    Article  CAS  PubMed  Google Scholar 

  • Carmeliet P, Mackman N, Moons L et al (1996) Role of tissue factor in embryonic blood vessel development. Nature 383:73–75

    Article  CAS  PubMed  Google Scholar 

  • Christie PD, Edelberg JM, Picard MH et al (1999) A murine model of myocardial thrombosis. J Clin Invest 104:533–539

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Connolly AJ, Ishihara H, Kahn ML et al (1996) Role of the thrombin receptor in development and evidence for a second receptor. Nature 381:516–519

    Article  CAS  PubMed  Google Scholar 

  • Cui J, O’Shea KS, Purkayastha A et al (1996) Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384:66–68

    Article  CAS  PubMed  Google Scholar 

  • Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kalebo P, Close P (1997) Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. The Journal of bone and joint surgery American volume 79(3):326–333

    CAS  PubMed  Google Scholar 

  • Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, et al. (1993) Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. Journal of the American College of Cardiology 21(5):1039–1047

    Article  CAS  PubMed  Google Scholar 

  • Evans JP, Brinkhous KM, Brayer GD et al (1989) Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A 86:10095–10099

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Healy AM, Rayburn HB, Rosenberg RD, Weiler H (1995) Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A 92:850–854

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Herzog RW, Yang EY, Couto LB et al (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5:56–63

    Article  CAS  PubMed  Google Scholar 

  • Hodivala-Dilke KM, McHugh KP, Tsakiris DA et al (1999) β 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103:229–238

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Huang Z-F, Higuchi D, Lasky N, Broze GJJ (1997) Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90:944–951

    CAS  PubMed  Google Scholar 

  • Kahn ML, Zheng Y-W, Huang W et al (1998) A dual thrombin receptor system for platelet activation. Nature 394:690–694

    Article  CAS  PubMed  Google Scholar 

  • Kay MA, Manno CS, Ragni MV et al (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients with an AAV vector. Nat Genet 24:257–261

    Article  CAS  PubMed  Google Scholar 

  • Kung J, Hagstrom J, Cass D et al (1998) Human FIX corrects bleeding diathesis of mice with hemophilia B. Blood 91:784–790

    CAS  PubMed  Google Scholar 

  • Law DA, DeGuzman FR, Heiser P et al (1999) Integrin cytoplasmic tyrosine motif is required for outside-in αllbβ3 signalling and platelet function. Nature 401:808–811

    Article  CAS  PubMed  Google Scholar 

  • Leon C, Hechler B, Freund M et al (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J Clin Invest 104:1731–1737

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Lin H-F, Maeda N, Sithies O et al (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90:3962–3966

    CAS  PubMed  Google Scholar 

  • Offermanns S, Toombs CF, Hu Y-H, Simon MI (1997) Defective platelet activation in Gα q-deficient mice. Nature 389:183–186

    Article  CAS  PubMed  Google Scholar 

  • Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 95(4):846–854

    CAS  PubMed  Google Scholar 

  • Ploplis VA, Carmeliet P, Vazirzadeh S et al (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92:2585–2593

    Article  CAS  PubMed  Google Scholar 

  • PRISM Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. The New England journal of medicine 338(21):1498–1505. doi:10.1056/NEJM199805213382103

    Article  Google Scholar 

  • Subramaniam M, Frenette PS, Saffaripour S et al (1996) Defects in hemostasis in P-selectin-deficient mice. Blood 87:1238–1242

    CAS  PubMed  Google Scholar 

  • Thomas DW, Mannon RB, Mannon PJ et al (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102:1994–2001

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Toomey JR, Kratzer KE, Lasky NM et al (1996) Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88:1583–1587

    CAS  PubMed  Google Scholar 

  • Vassalli G, Dichek DA (1997) Gene therapy for arterial thrombosis. Cardiovasc Res 35:459–469

    Article  CAS  PubMed  Google Scholar 

  • Waugh JM, Yuksel E, Li J et al (1999) Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 84:84–92

    Article  CAS  PubMed  Google Scholar 

  • Zoldhelyi P, McNatt J, Shelat HS et al (2000) Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 101:289–295

    Article  CAS  PubMed  Google Scholar 

Safety Assays in Thrombosis and Haemostasis

  • Mousa SA (2013) Blood Constituents and Safety Pharmacology. In: Vogel HG, Maas J, Hock FJ, Mayer D (eds) Drug Discovery and Evaluation–Safety and Pharmacokinetic Assays, 2nd ed. Springer-Verlag, Berlin Heidelberg New York, pp 311–391

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive, Albany, NY, 12144, USA

    Shaker A. Mousa

Authors
  1. Shaker A. Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaker A. Mousa .

Editor information

Editors and Affiliations

  1. CorDynamics, Dieburg, Germany

    Franz J. Hock

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

Mousa, S.A. (2016). Critical Issues in Experimental Models. In: Hock, F. (eds) Drug Discovery and Evaluation: Pharmacological Assays. Springer, Cham. https://doi.org/10.1007/978-3-319-05392-9_16

Download citation

Publish with us

Policies and ethics

Search

Navigation